Indonesia and Russia are in discussions to collaborate on pharmaceutical technology transfers, aiming to bolster Indonesia’s domestic medicine production capabilities and reduce its dependency on imports. The talks, which involved Indonesia’s Food and Drug Authority (BPOM) and Russia’s Deputy Minister of Industry and Trade, focused on enhancing pharmaceutical manufacturing, regulatory oversight, and utilizing digital technologies for safer and more traceable products.
During the discussions, Indonesia underscored the need to expand local production of essential healthcare products, particularly diabetes treatments such as insulin and glucagon-like peptide-1 (GLP-1) medicines. Potential areas for cooperation also include cancer treatments, monoclonal antibodies, antiviral medicines, and advanced biotechnology products.
Russian pharmaceutical companies have shown interest in transferring technology to Indonesia and possibly establishing manufacturing facilities for insulin, oncology medicines, and biotechnology products. The Russian delegation noted that several companies have already submitted product registration documents to BPOM.
Both countries reviewed their existing partnerships in Good Manufacturing Practice (GMP) inspections, technical training, and information sharing. A proposed memorandum of understanding aims to create a framework for deeper collaboration, including a Russian proposal to explore mutual recognition of GMP certificates to ease regulatory processes and facilitate market access in both nations.
To enhance Indonesia’s inspection capabilities, Russia offered technical training featuring virtual reality-based simulations to better prepare inspectors for pharmaceutical manufacturing assessments. The discussions also touched upon digital regulatory systems and supply-chain monitoring, with both parties expressing an interest in continuing negotiations and planning further visits to pharmaceutical manufacturing facilities.